Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), is upbeat about the company’s pipeline for debilitating diseases like multiple sclerosis, including the investigational asset ofatumumab, which he believes has the potential to offer “B cell therapy 2.0” in MS. Aradhye had earlier played a pivotal role for Gilenya (fingolimod) as its Senior Global Program Medical Director.
Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations
Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), outlines the company’s all-encompassing-approach for multiple sclerosis therapies. In a wide-ranging interview with Scrip, Aradhye also touches on the promise of gene therapy and how emerging technologies are helping shape medical innovation.
More from Business
• By
Sun Pharma sees opportunities for Antibe’s otenaproxesul in the US and emerging markets and aims to get the clinical hold on the novel NSAID lifted. The firm is also focusing on its specialty business in Japan, amid pricing challenges for long-listed products.
• By
Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
• By
Amgen saw revenue rise 19% to $33.4bn in 2024 and said revenue should grow to $34.3bn-$35.7bn in 2025 despite losing exclusivity for its biggest franchise – Prolia and Xgeva (denosumab) – this year.
More from Scrip
• By
The drug maker withdrew its goal of $11bn in sales for the HPV vaccine and paused shipments to China so that partner Zhifei can reduce its inventory.
• By
The Association for Accessible Medicines has urged the Trump administration not to impose proposed tariffs on the off-patent drug sector to avoid drug shortages and additional costs for manufacturers.
• By
Pfizer CFO Dave Denton said the company is in a position to do bigger deals in 2025 during the company’s fourth quarter sales and earnings call.
